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Introduction
The use of radiation therapy (RT) has led to significant improvements in survival for patients treated for breast cancer, Hodgkin's disease, and numerous other malignancies [1] . However, as patients live longer, the potentially serious long term adverse effects of radiation on the heart have raised concerns. Irradiation of a substantial volume of the heart to a sufficiently high dose can damage virtually any component of the heart including the pericardium, myocardium, heart valves, coronary arteries, capillaries and conducting system. Pericarditis is the typical acute manifestation of radiation injury, while chronic pericardial disease, coronary artery disease, cardiomyopathy, valvular disease and conduction abnormalities can manifest years after the original treatment. Analyses have shown that therapeutic benefits from RT may be offset to some extent by delayed effects on the heart.
Pathophysiology
The clinical spectrum of cardiac injury directly resulting from radiation includes the following abnormalities: Acute pericarditis during therapy (rarely associated with treatment of juxtapericardial cancer); delayed pericarditis that can present abruptly or as chronic pericardial effusion or constriction; pancarditis, which includes pericardial and myocardial fibrosis with or without endocardial fibroelastosis; cardiomyopathy in the absence of significant pericardial disease; diastolic dysfunction and other abnormalities (functional valve injury, conduction defects, Coronary artery disease (CAD)) [2] .
The histologic hallmarks of radiation associated cardiotoxicity are diffuse fibrosis in the intersititium of the myocardium with normal appearing myocytes and narrowing of capillary and arterial lumens [3] . Irregularities of endothelial cell membranes, cytoplasmic swelling, thrombosis, and rupture of the walls are present. The ratio of capillaries to myocytes is reduced by approximately 50 percent and this reduction leads to myocardial cell death, ischemia, and fibrosis. Dense collagen and fibrin replace the normal adipose tissue of the outer layer of the heart leading to pericardial fibrosis [4] .
The essential charecteristics of the radiation-induced CAD are premature CAD, disproportionate number of coronary ostial lesions, and predilection for the right coronary (RCA) , left main and proximal left anterior descending coronary arteries [5] . Since the greatest amount of radiation exposure occurs in the anterior wall of the chest during irradiation, radiation-induced CAD has been frequently detected in the proximal parts of all epicardial coronary arteries. In histopathologic examination, fibrointimal thickening without a lipid core is common in radiation-induced injury.
The cusps and valve leaflets may undergo fibrotic changes with or without calcification. Myocardial fibrosis can compromise cardiac compliance leading to diastolic dysfunction and fibrosis of cells in the conduction system may predispose to dysrhythmia.
Clinical Course and Management
Exposure at a young age, anterior irradiation without shielding, a high dose of total irradiation, and the presence of other radiation induced heart diseases are the risk factors in thedevelopment of radiation induced CAD [6] .
In the late 1980s, data demonstrated that older radiotherapy techniques resulted in increased rates of cardiac morbidity and mortality. A meta-analysis of nearly 20,000 women with breast cancer enrolled into 40 randomized trials before 1990 showed that radiotherapy reduced the annual mortality from breast cancer by 13%, but increased the annual mortality rate from other causes by 21%, mostly from vascular causes [7] . Similarly, another review of nearly 8,000 cases from 10 randomized trials of mastectomy with or without radiotherapy initiated before 1975 and found the standardized mortality ratio was significantly higher for patients treated with radiotherapy compared with controls [3] . A meta-analysis by the Early Breast Cancer Trialists' Collaborative Group that included 78 randomized trials of breast or chest wall irradiation after surgery examined the risk of death from breast cancer and non-breast cancer causes [8] . In this analysis, there was an excess of non-breast cancer deaths among women who received radiation, mainly due to heart disease and lung cancer. The excess mortality was seen only after 5 years after treatment, and was not age dependent. The studies included were conducted between 1961 and 1995, and many of the older trials used outdated radiation techniques that exposed more volume of heart and lung to larger doses of irradiation than current standard tangential beams, accounting for the excess cardiovascular mortality. Hooning et al. examined the long-term cardiovascular disease (CVD) risk according to specific radiation fields and interaction with known CVD risk factors among 4,414 10-year survivors of breast cancer treated from 1970 through 1986 in the Netherlands [9] . After 18 years' median follow-up, 62.9 excess cases per 10,000 patient years of cardiovascular events were observed compared with the general female population. In addition, radiotherapy to either the left or right side of the internal mammary chain was associated with increased cardiovascular disease for 1970 to 1979 compared with patients who received no radiotherapy. After 1979, radiation in combination with chemotherapy was associated with a greater risk of heart failure than patients who received radiotherapy only. Finally, when combined, smoking and radiotherapy were associated with an additive effect on risk of Myocardial Infarction (MI) [9] . Giordano et al. reported that the 15-year CVD mortality rate was significantly greater for left-sided versus right-sided tumors for women diagnosed and treated between 1973 and 1979 (13% vs. 10.2%) [10] . However there were no significant differences for women diagnosed and treated after 1984 with newer radiotherapy techniques. Although modern radiation techniques provide lower cardiac mortality risks than older techniques, cardiopulmonary damage does nonetheless occur. Prospective studies report cardiac perfusion defects in 50% to 63% of women and radiologic evidence of irreversible lung fibrosis and associated pulmonary disorders with left-sided breast cancer 6 to 24 months after radiotherapy [11] . Focal impairment of cardiac perfusion in the left ventricle has been described after chest wall irradiation [12] . The frequency with which this might occur was addressed in a report of 114 patients: perfusion defects were seen in 10 to 20% of patients when less than 5% of the left ventricle was included in the radiation field, versus 50 to 60% when more than 5% was included. These perfusion defects were associated with wall-motion abnormalities but not a reduction in left ventricular ejection fraction. Risk factors for radiation-induced cardiovascular morbidity and mortality go beyond the myocardial and/ or pulmonary volume in the field and the dose delivered to that field (dose-volume histogram), to include the presence of pre-existing CVD risk factors and use of anthracyclines [13] .
Controversy over whether radiation exposure of the heart results in coronary artery stenosis existed as aresult of a high prevalance of the disease. However, a number of large cohort studies have demonstrated that the incidence of CAD is significantly higher in patients with prior radiation therapy compared with age-matched control groups with a preponderance of very charecteristic lesions [3, 4, 14] . Relative risk in those studies is reported to be varied between 3 to 40, depending the age of the cohort. In animal models, the primary target of radiation for this complication is the endothelial cell. The presence of other risk factors such as dyslipidemia, may have an impact on the development of radiation-induced cardiac injury. As an example, an increase in coronary atherosclerosis has been noted when animals are fed a high cholesterol diet and then exposed to radiation [1] . In humans, CAD, usually involving the left anterior descending artery, has been observed after radiation doses of 24 Gy or higher (1). In addition, patients receiving 1.6 to 3.9 Gy to the heart for treatment of benign conditions were observed to have an increased risk of late coronary heart disease [15] . The muscular coronary arteries are large enough to escape damage by therapeutic doses of thoracic radiation, and coronary thrombosis is a relatively infrequent occurrence. However, radiation therapy can cause endothelial dysfunction, a result of endothelial cell death and a decreased availability of nitric oxide; this may contribute to the subsequent development of arterial occlusion and vascular events [16] . A number of pro-inflammatory molecules have been reported to be upregulated by endothelial cell irradiation in vitro and in vivo. These are adhesion molecules, including E-selectin (a mediator of leukocyte rolling), ICAM (a mediator of leukocyte arrest), and PECAM-1 (involved in leukocyte transmigration). These pro-inflammatory events may be the molecular correlate of early radiation-induced ultrastructural changes observed in the microvessels of the myocardium [17] . Besides induction of adhesion molecules, up-regulation of some cytokines (namely IL-6 and IL-8) has been observed after endothelial cell irradiation in a time-and dose-related fashion [18] . Also, there is evidence of prothrombic effects of radiation, which may be the cause of the increased platelet adherence and thrombus formation observed in irradiated capillaries and arteries [19] . The carotid arteries of apolipoproteinnegative mice have been monitored for the development of atherosclerotic plaques for up to 9 months after high doses of irradiation. Irradiation had no influence on cholesterol levels, markers of systemic inflammation, or atherosclerotic lesions in the non-irradiated renal arteries, but initial plaque formation began earlier and the rate of plaque growth was faster in irradiated than in non-irradiated carotid arteries. Histologically, the carotid arteries showed typical signs of plaque instability, such as intra-plaque haemorrhage and macrophage accumulation. The interaction of radiation-induced changes in endothelial function with the initial events of atherosclerotic lesion formation in these animals was believed to result in chronic inflammation, favouring the development of a vulnerable plaque [20] .
On the other hand, concurrent chemotherapy administration can also influence radiation toxicity on the heart. Combinations of doxorubicin and radiation resulted in additive but not synergistic effects in a rabbit model [21] . Oxidative damage to the heart, induced both by radiation and doxorubicin, may be a pathogenic factor [22] . In humans, prior mediastinal radiation may increase the susceptibility to anthracycline cardiotoxicity by inducing endothelial cell damage and eventual compromise in coronary artery blood flow [1] .
The management of radiation induced CAD is similar to commonly occurring CAD. Although surgery is effective, it is often complicated by mediastinal fibrosis in the majority of patients with the history of prior anterior irradiation [2] . Therefore PCI in those patients may be primary treatment option especially when bypass surgery is difficult to perform [2] .
Conclusion
The risk of developing adverse cardiac events is among one of the long term complications of chest RT which may limit the benefits of the therapy. Although safer ways to irradiate the chest are being studied and developed, the long term morbidity and mortality associated with modern techniques are still to be determined. Since the latency period for the cardiovasvular complications may take more than a decade to become clinically manifested, long term clinical screening studies are necessary to establish the safety profiles of the newer RT methods.
